458 related articles for article (PubMed ID: 33508516)
1. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator.
Maron BJ; Rowin EJ; Maron MS
Heart Rhythm; 2021 Jun; 18(6):1012-1023. PubMed ID: 33508516
[TBL] [Abstract][Full Text] [Related]
2. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
Maron BJ; Maron MS
Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314
[TBL] [Abstract][Full Text] [Related]
3. The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy.
Maron MS; Rowin EJ; Maron BJ
Am J Cardiol; 2024 Feb; 212S():S64-S76. PubMed ID: 38368038
[TBL] [Abstract][Full Text] [Related]
4. Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy.
Maron BJ; Rowin EJ; Maron MS
Circ Res; 2019 Aug; 125(4):370-378. PubMed ID: 31518168
[TBL] [Abstract][Full Text] [Related]
5. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
6. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
[TBL] [Abstract][Full Text] [Related]
7. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
8. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
9. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
[TBL] [Abstract][Full Text] [Related]
10. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
11. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
12. Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy.
Rowin EJ; Sridharan A; Madias C; Firely C; Koethe B; Link MS; Maron MS; Maron BJ
Am J Cardiol; 2020 Aug; 128():75-83. PubMed ID: 32650928
[TBL] [Abstract][Full Text] [Related]
13. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
Maron MS; Rowin EJ; Wessler BS; Mooney PJ; Fatima A; Patel P; Koethe BC; Romashko M; Link MS; Maron BJ
JAMA Cardiol; 2019 Jul; 4(7):644-657. PubMed ID: 31116360
[TBL] [Abstract][Full Text] [Related]
14. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.
Maron BJ; Casey SA; Chan RH; Garberich RF; Rowin EJ; Maron MS
Am J Cardiol; 2015 Sep; 116(5):757-64. PubMed ID: 26183790
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM].
Maron BJ; Spirito P
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):297-302. PubMed ID: 19791462
[TBL] [Abstract][Full Text] [Related]
16. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ
Circ J; 2010 Nov; 74(11):2271-82. PubMed ID: 20962423
[TBL] [Abstract][Full Text] [Related]
17. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
[TBL] [Abstract][Full Text] [Related]
18. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
[TBL] [Abstract][Full Text] [Related]
19. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
[TBL] [Abstract][Full Text] [Related]
20. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
